Enhanced evasion of neutralizing antibody response by Omicron XBB.1.5, CH.1.1, and CA.3.1 variants
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Enhanced evasion of neutralizing antibody response by Omicron XBB.1.5, CH.1.1, and CA.3.1 variants
Authors
Keywords
-
Journal
Cell Reports
Volume 42, Issue 5, Pages 112443
Publisher
Elsevier BV
Online
2023-04-18
DOI
10.1016/j.celrep.2023.112443
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Antivenom for Severe Scorpion Envenomation in Arizona
- (2023) Stephen A. Klotz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against Omicron SARS-CoV-2
- (2022) Hongjie Xia et al. Cell Host & Microbe
- Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts tropism and fusogenicity
- (2022) Bo Meng et al. NATURE
- Considerable escape of SARS-CoV-2 Omicron to antibody neutralization
- (2022) Delphine Planas et al. NATURE
- Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron
- (2022) Huiping Shuai et al. NATURE
- SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo
- (2022) Kenrie P. Y. Hui et al. NATURE
- Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant
- (2022) Rigel Suzuki et al. NATURE
- Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination
- (2022) Eddy Pérez-Then et al. NATURE MEDICINE
- Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection
- (2022) John P. Evans et al. Science Translational Medicine
- Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies
- (2022) Xun Wang et al. Emerging Microbes & Infections
- SARS-CoV-2 Omicron sublineages show comparable cell entry but differential neutralization by therapeutic antibodies
- (2022) Prerna Arora et al. Cell Host & Microbe
- Neutralization of SARS-CoV-2 Omicron sub-lineages BA.1, BA.1.1, and BA.2
- (2022) John P. Evans et al. Cell Host & Microbe
- Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529
- (2022) Tongqing Zhou et al. SCIENCE
- Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum
- (2022) Aekkachai Tuekprakhon et al. CELL
- Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5
- (2022) Qian Wang et al. NATURE
- BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection
- (2022) Yunlong Cao et al. NATURE
- Neutralization of the SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants
- (2022) Panke Qu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5
- (2022) Nicole P. Hachmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pathogenicity, transmissibility, and fitness of SARS-CoV-2 Omicron in Syrian hamsters
- (2022) Shuofeng Yuan et al. SCIENCE
- Virological characteristics of the SARS-CoV-2 Omicron BA.2 subvariants, including BA.4 and BA.5
- (2022) Izumi Kimura et al. CELL
- Evasion of neutralizing antibody responses by the SARS-CoV-2 BA.2.75 variant
- (2022) Panke Qu et al. Cell Host & Microbe
- Durability of Booster mRNA Vaccine against SARS-CoV-2 BA.2.12.1, BA.4, and BA.5 Subvariants
- (2022) Panke Qu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Omicron BA.2 breakthrough infection enhances cross-neutralization of BA.2.12.1 and BA.4/BA.5
- (2022) Alexander Muik et al. Science Immunology
- Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants
- (2022) Qian Wang et al. CELL
- Enhanced neutralization resistance of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2
- (2022) Panke Qu et al. Cell Host & Microbe
- Humoral immune evasion of the omicron subvariants BQ.1.1 and XBB
- (2022) Ryuta Uraki et al. LANCET INFECTIOUS DISEASES
- Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster
- (2022) Chaitanya Kurhade et al. NATURE MEDICINE
- Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster
- (2022) Meredith E. Davis-Gardner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Diminished neutralization responses towards SARS-CoV-2 Omicron VoC after mRNA or vector-based COVID-19 vaccinations
- (2022) Henning Jacobsen et al. Scientific Reports
- CoV-Spectrum: analysis of globally shared SARS-CoV-2 data to identify and characterize new variants
- (2021) Chaoran Chen et al. BIOINFORMATICS
- Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar
- (2021) Laith J. Abu-Raddad et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation
- (2021) Akatsuki Saito et al. NATURE
- Plasma Neutralization of the SARS-CoV-2 Omicron Variant
- (2021) Fabian Schmidt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody
- (2020) Dora Pinto et al. NATURE
- Neutralizing antibody against SARS-CoV-2 spike in COVID-19 patients, health care workers and convalescent plasma donors
- (2020) Cong Zeng et al. JCI Insight
- Automated comparative protein structure modeling with SWISS-MODEL and Swiss-PdbViewer: A historical perspective
- (2010) Nicolas Guex et al. ELECTROPHORESIS
- Quantitative Comparison of HTLV-1 and HIV-1 Cell-to-Cell Infection with New Replication Dependent Vectors
- (2010) Dmitriy Mazurov et al. PLoS Pathogens
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now